Recent Advances in Modified Cap Analogs for mRNA Vaccine Development

Strategic Insights -

Researchers at Thermo Fisher Scientific Inc. have made significant progress in the synthesis of various cap analogs, with potential applications in mRNA vaccine development for COVID-19. The study highlights the importance of chemically modified mRNA cap analogs in enhancing translational efficiency and binding affinity. The development of trinucleotide cap analogs has shown promising results, surpassing dinucleotide cap analogs in terms of capping efficiency and translational properties.

Key Takeaways:

  • The recent FDA approval of the mRNA vaccine for severe acute respiratory syndrome coronavirus (SARS-CoV-2) emphasizes the importance of mRNA in therapeutic applications.
  • The chemically modified mRNA cap analogs contain a unique cap structure, m(7)G[5 ']ppp[5 ']N, present at the 5 '-end of many eukaryotic cellular and viral RNAs and several non-coding RNAs.
  • The chemical modifications on cap analog influence orientation's nature, translational efficiency, nuclear stability, and binding affinity.
  • Trinucleotide cap analogs outweigh dinucleotide cap analogs in terms of capping efficiency and translational properties.
  • The synthesis of various dinucleotide cap analogs, such as dinucleotide containing a triazole moiety, phosphorothiolate cap, biotinylated cap, cap analog containing N1 modification, cap analog containing N2 modification, and dinucleotide containing fluorescence probe and TAT, has been reported.
  • The biological applications of these novel cap analogs are delineated, including their use in mRNA-based vaccines.
  • The research has been peer-reviewed and published in The Chemical Record, 2022.

Statistics:

  • The study focuses on the synthesis of various dinucleotide and trinucleotide cap analogs.
  • The trinucleotide cap analogs show higher capping efficiency and translational properties compared to dinucleotide cap analogs.
  • The research highlights the importance of chemically modified mRNA cap analogs in enhancing translational efficiency and binding affinity.

Sources:

  • NewsRx. Researchers at Thermo Fisher Scientific Inc. Target COVID-19 (Recent Advances In Modified Cap Analogs: Synthesis, Biochemical Properties, and Mrna Based Vaccines). Asia Business Newsweekly. May 10, 2022; p 762.
  • Recent Advances In Modified Cap Analogs: Synthesis, Biochemical Properties, and Mrna Based Vaccines. The Chemical Record, 2022.
  • Thermo Fisher Scientific Inc. Life Sci Solut Grp, 2130 Woodward St, Austin, TX 78744, United States.